Sun Pharma Clinches DCGI Nod for ‘Noveltreat’: India’s First Generic Weight-Loss Blockbuster

In a landmark development for the Indian healthcare landscape, Sun Pharmaceutical Industries Ltd. has officially received approval from the Drugs Controller General of India (DCGI) to manufacture and market Noveltreat, a generic version of the global sensation semaglutide. The approval, announced on January 27, 2026, marks the first time a domestic generic for chronic weight management has been cleared for the Indian market, setting the stage for a dramatic shift in how obesity is treated in the country.

The ‘Noveltreat’ Advantage: Launch & Dosage

Noveltreat is a GLP-1 receptor agonist that works by mimicking hormones that target areas of the brain that regulate appetite and food intake.

Feature	Requirement Details
Brand Name	Noveltreat
Active Ingredient	Semaglutide (Generic version of Wegovy)
Indication	Chronic Weight Management (Adjunct to diet/exercise)
Launch Timeline	Post March 20, 2026 (Following patent expiry)
Administration	Once-weekly subcutaneous injection via prefilled pen

Strengths for Precision Dosing:

To minimize gastrointestinal side effects, patients typically start on a low dose and escalate. Sun Pharma will offer the drug in five convenient strengths:

Initial/Titration: 0.25 mg, 0.5 mg, and 1 mg
Maintenance: 1.7 mg and 2.4 mg (Standard weekly maintenance)

Sun Pharma’s Strategic Dual-Brand Approach

The company has successfully executed a two-pronged regulatory strategy to dominate the GLP-1 segment in India. Following a fierce legal battle in the Delhi High Court, Sun Pharma is now positioned to launch two separate brands as soon as the innovator’s patent “cliff” occurs in March.

Noveltreat: Indicated for Weight Management (High-dose semaglutide).
Sematrinity: Approved in December 2025 for Type 2 Diabetes (Lower-dose management).

Addressing a “Metabolic Crisis”

With nearly 25% of the Indian population classified as overweight or obese (NFHS-5), and over 101 million living with diabetes, the demand for effective metabolic therapies is at an all-time high.

“Obesity and diabetes are the most pressing health challenges in India today. Noveltreat meets global quality standards and is backed by robust Indian Phase III clinical data. We are committed to making these life-saving therapies accessible to the common man.” — Kirti Ganorkar, MD, Sun Pharma.

Market Dynamics: The 2026 Patent Cliff

The Indian semaglutide market is projected to be a ₹50,000 crore opportunity. While the innovator currently sells the drug at premium prices (approx. ₹14,000–₹16,000 per month), the entry of Sun Pharma, along with rivals like Dr. Reddy’s and Alkem, is expected to trigger a 30% to 50% price drop immediately, with potential long-term reductions of up to 70%.